PureTech Health plc
No SEC Form 4 filings for $PTCHF in the last 30 days.
See all $PTCHF insider activity →PureTech Health (PRTC) announced FDA Fast Track designation for LYT-200, an experimental therapy for relapsed/refractory high-risk myelodysplastic syndromes. The FDA feedback supports advancing LYT-200 into Phase 2 trials. The therapy, developed by Gallop Oncology, targets galectin-9 and will be evaluated in a Phase 2 study with 125 patients. PRTC shares closed at $16.00, down 3.03%.
PureTech announced positive topline data from its Phase 1b trial of LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML), showing complete responses and favorable tolerability. The company plans to prioritize R/R HR-MDS for further development and engage with the FDA for a potential registration-supporting trial. LYT-200, an anti-galectin-9 monoclonal antibody, demonstrated robust antileukemic activity, including a 45.5% overall response rate in HR-MDS patients.
PureTech Health PLC (NASDAQ:PRTC) stock dropped in premarket trading after the company received FDA feedback supporting advancement for its idiopathic pulmonary fibrosis (IPF) drug, deupirfenidone, into a pivotal Phase 3 trial. Despite the positive regulatory path, investor concern arose over the timeline, as the Phase 3 trial is not expected to start until the first half of 2026. The new trial aims for potential registration via a 505(b)(2) pathway, building on promising Phase 2b results.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PTCHF (PureTech Health plc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PTCHF coverage spans financial news and regulation.
Fast Track status may accelerate development and boost investor sentiment.
PureTech announced positive topline data from its Phase 1b trial of LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML), showing complete responses and favorable tolerability. The company plans to prioritize R/R HR-MDS for further development and engage with the FDA for a potential registration-supporting trial. LYT-200, an anti-galectin-9 monoclonal antibody, demonstrated robust antileukemic activity, including a 45.5% overall response rate in HR-MDS patients.
PureTech Health PLC (NASDAQ:PRTC) stock dropped in premarket trading after the company received FDA feedback supporting advancement for its idiopathic pulmonary fibrosis (IPF) drug, deupirfenidone, into a pivotal Phase 3 trial. Despite the positive regulatory path, investor concern arose over the timeline, as the Phase 3 trial is not expected to start until the first half of 2026. The new trial aims for potential registration via a 505(b)(2) pathway, building on promising Phase 2b results.
PureTech Health has launched Celea Therapeutics, a new biotech company focused on developing a respiratory disease treatment. Celea Therapeutics will advance deupirfenidone (LYT-100), an improved version of pirfenidone, for idiopathic pulmonary fibrosis and other inflammatory lung diseases. The drug has shown positive results in a Phase 2b trial and is moving toward Phase 3 discussions with the FDA.
PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AlphAI scores every news story that mentions PTCHF with an AI model for sentiment and relevance, and aggregates insider trades from PureTech Health plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
PureTech Health (PRTC) announced FDA Fast Track designation for LYT-200, an experimental therapy for relapsed/refractory high-risk myelodysplastic syndromes. The FDA feedback supports advancing LYT-200 into Phase 2 trials. The therapy, developed by Gallop Oncology, targets galectin-9 and will be evaluated in a Phase 2 study with 125 patients. PRTC shares closed at $16.00, down 3.03%.
2 min readPureTech announced positive topline data from its Phase 1b trial of LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML), showing complete responses and favorable tolerability. The company plans to prioritize R/R HR-MDS for further development and engage with the FDA for a potential registration-supporting trial. LYT-200, an anti-galectin-9 monoclonal antibody, demonstrated robust antileukemic activity, including a 45.5% overall response rate in HR-MDS patients.
4 min readPureTech Health PLC (NASDAQ:PRTC) stock dropped in premarket trading after the company received FDA feedback supporting advancement for its idiopathic pulmonary fibrosis (IPF) drug, deupirfenidone, into a pivotal Phase 3 trial. Despite the positive regulatory path, investor concern arose over the timeline, as the Phase 3 trial is not expected to start until the first half of 2026. The new trial aims for potential registration via a 505(b)(2) pathway, building on promising Phase 2b results.
4 min readPureTech Health has launched Celea Therapeutics, a new biotech company focused on developing a respiratory disease treatment. Celea Therapeutics will advance deupirfenidone (LYT-100), an improved version of pirfenidone, for idiopathic pulmonary fibrosis and other inflammatory lung diseases. The drug has shown positive results in a Phase 2b trial and is moving toward Phase 3 discussions with the FDA.
3 min readPureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min readImage source: The Motley Fool.Thursday, August 28, 2025, at 9 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readPureTech Health ( NASDAQ:PRTC ) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in consolidated operating expenses to $50 million from $66.7 million year-over-year in the first ...
3 min read
